First phase began in July 2017 and has just been completed
Moves strengthen existing analytical and bioanalytical drug development service offering
Supports qNMR facility in providing reference material characterisation and quantitative measurement research for customers
Making scientific innovation an intrinsic part of delivering a world-class NHS
Innovation team addresses significant measurement challenges
Effective extractables and leachables programmes help identify compounds present in components in direct contact with a drug product
LGC operates out of 22 countries, with laboratories and centres across Europe and the US, as well as sites in Brazil, China and India.